A Review of Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prevention and Treatment of COVID-19

American Journal of Therapeutics: 2021 May/June - Volume 28 - Issue 3 - pe299-e318

doi: 10.1097/MJT.000000000000001377

Commentary

The vast majority of randomized, observational controlled trials of ivermectin have repeatedly reported substantial improvements in clinical outcomes.

A number of prevention trials have shown that regular use of ivermectin leads to a significant reduction in infections.

Several large "natural experiments" have occurred in areas where "ivermectin distribution" campaigns have been initiated, and progress has been reported in these studies that have subsequently shown closely reproducible reductions in the number of cases and fatality rates over time compared to neighboring areas without such campaigns.

The conclusions of this study also show that a meta-analysis based on 18 randomized controlled trials of ivermectin for COVID-19 confirmed significant statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance.

In addition, results from a number of controlled prevention trials report a significant reduction in the risk of contracting COVID-19 with regular use of ivermectin.

Taken together, the many case reports from the ivermectin distribution campaign indicate that an effective oral agent has been identified for all stages of COVID-19.